{'fraction_non_alphanumeric': 0.013371537726838587, 'fraction_numerical': 0.0, 'mean_word_length': 5.469135802469136, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Value of the use of the oral route versus the injectable route for fluoroquinolones. Pharmacoeconomic incidence and bibliographical study].

The aim of this study was to research the optimal conditions to shift to oral from injectable administration route for the fluoroquinolone antibiotics and the pharmacoeconomic and therapeutic impact of such a shift. Two indicators were used: proportion of the two administration routes, and mean cost per administration. The published results of pharmacokinetic studies in healthy and diseased subjects, and the clinical and/or pharmacokinetic studies including the notion of a therapeutic shift from the parenteral route to the oral route have been selected. The bioequivalence pharmacokinetic parameters of oral and injectable forms and the major clinical data of the therapeutic shift have been listed. Literature analysis reveals that there are few studies covering the specific assessment of the switch. The financial consequences of oral administration early use show the importance of such studies.